Page 7,148«..1020..7,1477,1487,1497,150..7,1607,170..»

Dogs who got stem cell therapy are well

Posted: Published on February 14th, 2012

WALKER, Mich. (WOOD) - Dogs who received the first in-clinic stem cell therapy in West Michigan returned to the vets who treated them Monday morning. Boris and Natasha returned to Kelley's Animal Clinic for their 60-day checkup after receiving stem cell treatment in December 2011. Dr. James Kelley and his staff of vets removed fat tissue from the dogs and activated it with an enzyme before injecting it into their back legs. This adult animal stem cell technology is different from the controversial embryonic stem cell therapy. Kelley said both dogs are doing amazingly well and that the procedure has done more than just help their arthritis. "We're finding that not only the joints are affected, the rest of the animal is affected as well," said Kelley. "The skin is better. The attitude in these dogs is much improved." Kelley and his staff have done 16 stem cell treatments since the first on Boris and Natasha, and he said all the dogs are showing signs of improvement after a short period of time. Here is the original post: Dogs who got stem cell therapy are well … Continue reading →

Posted in Cell Therapy | Comments Off on Dogs who got stem cell therapy are well

Stem Cell Treatment Might Reverse Heart Attack Damage

Posted: Published on February 14th, 2012

MONDAY, Feb. 13 (HealthDay News) -- Stem cell therapy's promise for healing damaged tissues may have gotten a bit closer to reality. In a small, early study, heart damage was reversed in heart-attack patients treated with their own cardiac stem cells, researchers report. The cells, called cardiosphere-derived stem cells, regrew damaged heart muscle and reversed scarring one year later, the authors say. Up until now, heart specialists' best tool to help minimize damage following a heart attack has been to surgically clear blocked arteries. "In our treatment, we dissolved scar and replaced it with living heart muscle. Such 'therapeutic regeneration' has long been the holy grail of cell therapy, but had never been accomplished before; we now seem to have done it," said study author Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles. However, outside experts cautioned that the findings are preliminary and the treatment is far from ready for widespread use among heart-attack survivors. The study, published online Feb. 14 in The Lancet, involved 25 middle-aged patients (average age 53) who had suffered a heart attack. Seventeen underwent stem cell infusions while eight received standard post-heart attack care, including medication and exercise therapy. The stem … Continue reading →

Posted in Cell Therapy | Comments Off on Stem Cell Treatment Might Reverse Heart Attack Damage

Save Money and Live Better with New Cost-Effective Thermobalancing Therapy by Treating Prostate Enlargement Naturally …

Posted: Published on February 14th, 2012

With new Thermobalancing Therapy men will not only save money by not purchasing kilograms of medicines but will feel better, Fine Treatment reveals. Why is a man so quickly turn to drugs to treat prostate enlargement? Before he goes to a drug, why not treat BPH with the Thermobalancing Therapy naturally? Why do waste thousands of dollars? London, UK (PRWEB) February 12, 2012 There is no need for men to rush to take BPH drugs and to deal with side effects later when he can use new Thermobalancing Therapy, Fine Treatment reveals. Men should be aware that the longer-term use of prescription drugs to the treatment of prostate enlargement can have serious negative side effects. Furthermore, men won’t have to spend money to the useless pills. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), “treatments with medication usually start at a low dose. Later on the dose gradually increases as medication typically cannot improve the condition of a growing prostate gland. Consequently, it increases the risk of side effects, such as erectile dysfunction or impotence, headache and fatigue, weight gain and depression.” However, according to the Consumer Reports, treating BPH with medication can run more … Continue reading →

Posted in Drug Side Effects | Comments Off on Save Money and Live Better with New Cost-Effective Thermobalancing Therapy by Treating Prostate Enlargement Naturally …

Whitney Houston and Other Musical Stars We Lost Too Soon

Posted: Published on February 14th, 2012

The world was stunned when on Saturday, February 11, 2012 an announcement was made that legendary singer Whitney Houston passed away at 3:55 p.m. Currently, the cause of her death is unknown. She's had a long-standing battle with drugs and alcohol and in May 2011, she entered rehab to receive treatment for alcohol and drug dependency. The music talent was discovered by Clive Davis in the 1980s and she went on to become a star in the film and music world. Whitney sold an incredible 200 million albums worldwide and received numerous awards and nominations including winning 30 Billboard Music Awards. The beauty was also one of the first women of color to be on the cover of Seventeen magazine. When one thinks of the star, the 1992 movie "The Bodyguard" and the song "I Will Always Love You" likely come to mind. There's no doubt her supreme talent won't be forgotten. At only 48-years-old, she's only the latest of a long line of incredible talents who we lost too soon. Amy Winehouse The singer was one of those talents who seemingly came out of nowhere and knocked listeners off their feet with her soulful vintage-sounding voice that hasn't been … Continue reading →

Posted in Drug Dependency | Comments Off on Whitney Houston and Other Musical Stars We Lost Too Soon

Whitney Houston death: Prescription drugs found in hotel room

Posted: Published on February 14th, 2012

The results of an autopsy performed Sunday were inconclusive, according to Winter, who denied reports that the coroner's office had told Houston's family that it had determined a cause of death. "We don't know yet," he said. Houston was found unresponsive Saturday afternoon in the bathtub of her suite. Authorities said they are trying to determine whether she drowned. Beverly Hills Fire Department paramedics performed CPR on Houston for about 20 minutes before declaring her dead, officials said. PHOTOS: Stars react People who were briefed on the probe Sunday said drowning was one of several scenarios that investigators are exploring. The sources stressed that investigators still have many unanswered questions, particularly about what Houston was doing in the hours before her death. Investigators are also interviewing family members and friends to determine whether Houston had any underlying medical conditions, said the sources, who spoke to The Times on the condition of anonymity because they were not authorized to disclose information about the case. One person with knowledge of the case said that although Houston was found in the bathtub, officials were still unsure whether she died of natural causes or was in some other way stricken. Winter said Sunday that … Continue reading →

Posted in Drugs | Comments Off on Whitney Houston death: Prescription drugs found in hotel room

ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from …

Posted: Published on February 13th, 2012

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of third patient in its Phase 1/2 trial for Stargardt’s macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient was treated on Monday (Feb. 6) by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and retina division chief at UCLA’s Jules Stein Eye Institute. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully. “With the treatment of this third Stargardt’s patient at Jules Stein Eye Institute, we have now completed the treatment of the first cohort of patients under our clinical protocol for phase I/II of our U.S. SMD trial,” said Gary Rabin, chairman and chief executive officer of ACT. “We will continue to regularly monitor the three SMD patients in this trial, and by early spring anticipate review of their progress and safety-related data by the Data and Safety Monitoring Board (DSMB). With approval of the DSMB, we would then advance to the next cohort of patients and administer a … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from …

The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx®, a Cord Blood Stem Cell …

Posted: Published on February 13th, 2012

JERUSALEM--(BUSINESS WIRE)-- Gamida Cell announced today that the Gamida Cell-Teva Joint Venture (JV), equally held by Gamida Cell and Teva Pharmaceutical Industries, has enrolled the last of 100 patients in the international, multi-center, pivotal registration, Phase III clinical trial of StemEx, a cell therapy product in development as an alternative therapeutic treatment for adolescents and adults, with blood cancers such as leukemia and lymphoma, who cannot find a family related, matched bone marrow donor. StemEx is a graft of an expanded population of stem/progenitor cells, derived from part of a single unit of umbilical cord blood and transplanted by IV administration along with the remaining, non-manipulated cells from the same unit. Dr. Yael Margolin, president and chief executive officer of Gamida Cell, said, "The JV is planning to announce the safety and efficacy results of the Phase III StemEx trial in 2012 and to launch the product into the market in 2013. It is our hope that StemEx will provide the answer for the thousands of leukemia and lymphoma patients unable to find a matched, related bone marrow donor.” Dr. Margolin continued, “StemEx may be the first allogeneic cell therapy to be brought to market. This is a source of … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx®, a Cord Blood Stem Cell …

Researchers make breakthrough in stem cell research

Posted: Published on February 13th, 2012

The research is a collaborative effort involving UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN) and is led by UQ Clinical Research Centre's (UQCCR) Professor Nicholas Fisk. It revealed a new method to create mesenchymal stem cells (MSCs), which can be used to repair bone and potentially other organs. “We used a small molecule to induce embryonic stem cells over a 10 day period, which is much faster than other studies reported in the literature,” Professor Fisk said. “The technique also worked on their less contentious counterparts, induced pluripotent stem cells. “To make the pluripotent mature stem cells useful in the clinic, they have to be told what type of cell they need to become (pre-differentiated), before being administered to an injured organ, or otherwise they could form tumours. “Because only small numbers of MSCs exist in the bone marrow and harvesting bone marrow from a healthy donor is an invasive procedure, the ability to make our own MSCs in large number in the laboratory is an exciting step in the future widespread clinical use of MSCs. “We were able to show these new forms of stem cells exhibited all the characteristics of bone marrow stem cells and we are … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Researchers make breakthrough in stem cell research

CLC bio part of €12M EU grant to uncover the mechanisms that determine cell fate

Posted: Published on February 13th, 2012

BARCELONA, Spain & AARHUS, Denmark--(BUSINESS WIRE)-- Today European scientists are meeting to kick off the 4DCellFate project, funded by the European Commission under the FP7 program. The 4DcellFate project will tackle the question of how the Polycomb Repressive Complex (PRC) and Nucleosome Remodelling and histone Deacetylase (NuRD) complexes function across the genome and time during differentiation, by applying cutting-edge technologies, such as structural biology, microscopy, proteomics, high-throughput sequencing, and computational modeling. "Understanding how the PRC and NuRD complexes determine cell fate is a prerequisite for developing models for diseases, such as cancer, that can be used both for further research and for developing personalized medicine therapies." states Director of R&D at CLC bio, Dr. Roald Forsberg, and continues, "The 4DCellFate project is a truly interdisciplinary and innovative project that will generate a wealth of experimental data. We look forward to applying our expertise in building integrated bioinformatics frameworks for handling, visualizing, and integrating all this data and to build new computational models of diseases to help researchers better understand these mechanisms." ICREA Research Professor and group leader at the CRG in Barcelona, Luciano Di Croce, adds, "This network has brought together the optimal mix of expertise, laboratories, techniques, and resources … Continue reading →

Posted in Cell Medicine | Comments Off on CLC bio part of €12M EU grant to uncover the mechanisms that determine cell fate

ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from …

Posted: Published on February 13th, 2012

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of third patient in its Phase 1/2 trial for Stargardt’s macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient was treated on Monday (Feb. 6) by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and retina division chief at UCLA’s Jules Stein Eye Institute. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully. “With the treatment of this third Stargardt’s patient at Jules Stein Eye Institute, we have now completed the treatment of the first cohort of patients under our clinical protocol for phase I/II of our U.S. SMD trial,” said Gary Rabin, chairman and chief executive officer of ACT. “We will continue to regularly monitor the three SMD patients in this trial, and by early spring anticipate review of their progress and safety-related data by the Data and Safety Monitoring Board (DSMB). With approval of the DSMB, we would then advance to the next cohort of patients and administer a … Continue reading →

Posted in Cell Medicine | Comments Off on ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from …

Page 7,148«..1020..7,1477,1487,1497,150..7,1607,170..»